I
nhaled corticosteroids are the most effective antiinflammatory medications available for the longterm treatment of persistent asthma. 1 The use of inhaled corticosteroids reduces airway reactivity, the need for concurrent medications, the pathologic signs of airway inflammation in asthma (ie, impaired epithelial integrity and reduction in eosinophils and mast cells), and the frequency of acute asthma exacerbations requiring hospitalization. [2] [3] [4] [5] [6] The inhaled corticosteroids currently available in the United States include fluticasone propionate (FP), budesonide, triamcinolone acetonide (TAA), flunisolide, and beclomethasone dipropionate.
Because these inhaled corticosteroids have different glucocorticoid receptor kinetics, as well as dif-ferent pharmacokinetic and pharmacodynamic profiles, it is difficult to compare them on a microgramto-microgram basis. 7 As a result, the most recent asthma management guidelines issued by the National Institutes of Health (NIH) 1 have estimated comparative daily dose ranges for low-, medium-, and high-dose regimens of inhaled corticosteroids. The commonly prescribed treatment regimens of FP, 88 g bid (176 g/d), and FP, 220 g bid (440 g/d), fall within the low-and medium-dose ranges of FP, respectively. Similarly, the commonly prescribed treatment regimen of TAA, 200 g qid, or TAA, 400 g bid (800 g/d), falls within the lowdose range of TAA; TAA, 600 g bid (1,200 g/d), falls within the medium-dose range for TAA.
The NIH guidelines recommend a stepwise approach to asthma therapy based on asthma severity, with the initiation of an anti-inflammatory medication (eg, low-dose inhaled corticosteroid) for mild persistent asthma, followed by a step up to mediumdose inhaled corticosteroid or the concomitant use of low-dose inhaled corticosteroid and a long-acting bronchodilator for moderate persistent asthma. 1 This approach of adding a long-acting bronchodilator if a low dose of inhaled corticosteroid fails to maintain asthma control is based on several studies demonstrating that the addition of salmeterol (SL) in patients who remain symptomatic despite receiving low-dose beclomethasone dipropionate or low-dose FP was more effective in improving lung function and symptom control than doubling the dose of beclomethasone dipropionate or FP. 8 -10 Condemi et al 11 and Gross et al 12 have already demonstrated significantly greater increases in pulmonary function with medium-dose FP powder 500 g/d compared with low-dose TAA 800 g/d. The current 12-week study is the first study to compare the efficacies of medium-dose FP 440 g/d and medium-dose TAA 1,200 g/d as well as to evaluate the alternative treatment of low-dose FP and SL in patients with uncontrolled asthma despite treatment with low doses of TAA, beclomethasone dipropionate, or flunisolide.
Materials and Methods

Patient Selection
This study was conducted in pulmonary/allergy medicine clinics, but patients were not required to be under the care of a pulmonary/allergy specialist to be eligible for the study. Patients were nonsmokers Ն 12 years of age who had asthma as defined in accordance with American Thoracic Society criteria. 13 All patients required treatment with low doses of beclomethasone dipropionate (6 to 16 puffs/d [252 to 672 g/d]), TAA (6 to 10 puffs/d [600 to 1,000 g/d]), or flunisolide (4 puffs/d [1,000 g/d]) for at least 3 months preceding the study. The daily dosing schedule for the inhaled corticosteroid had to be constant for the 14-day run-in period prior to the study. All patients had an FEV 1 of 40 to 85% of predicted normal values for age, gender, and height. 14, 15 Reversibility of airway obstruction was demonstrated by Ն 15% increase in FEV 1 within 30 min after two puffs (180 g) of albuterol.
Patients were excluded for any of the following reasons: pregnancy or lactation; use of methotrexate, gold, cyclosporine, or azathioprine for control of asthma within 30 days prior to the study; use of inhaled cromolyn or inhaled nedocromil within 4 weeks prior to the study; use of oral or injectable corticosteroids within 4 weeks prior to the study; significant concomitant illness; or concurrent use of any other prescription or over-the-counter medication that might affect the course of asthma or interact with sympathomimetic amines.
Study Design
This randomized, double-blind, triple-dummy, parallel-group study was conducted at 50 clinical centers throughout the United States. All patients gave written informed consent, and the protocol was approved by an appropriate institutional review board for each clinical center.
Patients entered a 2-week screening or run-in period and continued their usual total daily dose of inhaled corticosteroid with a twice-daily treatment regimen. Previous bronchodilator therapy was replaced with albuterol aerosol (Ventolin Inhalation Aerosol; Glaxo Wellcome; Research Triangle Park, NC) to be used only as needed for relief of acute symptoms. If already part of their therapeutic regimen, theophylline was continued at their fixed dose. Patients recorded morning and evening PEF, number of nighttime awakenings due to asthma, and number of daily and nighttime puffs of albuterol used for breakthrough symptoms on diary cards. They also rated asthma symptoms (wheeze, shortness of breath, cough, chest tightness) according to the following 5-point scale: 0 ϭ no symptoms; 1 ϭ some symptoms present but caused no discomfort; 2 ϭ symptoms that caused little discomfort and did not interfere with normal daily activities; 3 ϭ symptoms that caused discomfort and interfered with at least one normal daily activity; and 4 ϭ symptoms that caused significant discomfort and prevented normal daily activity.
To be eligible for randomization, patients were required to have an FEV 1 within 40 to 65% of the predicted value with or without asthma symptoms at the end of the run-in period (baseline measurement). Patients who had an FEV 1 within 65.1 to 85% of the predicted value were required to meet additional symptom criteria based on diary card information. Patients were also required to demonstrate adequate compliance, discontinue asthma medications for the required period of time prior to visiting the clinic, and complete daily diary cards. Patients who experienced a clinical asthma exacerbation or acquired an upper/ lower respiratory tract infection during the screening period were not eligible for randomization to study medications.
Patients meeting all entry criteria discontinued their previous inhaled corticosteroid and were randomly assigned to receive one of three inhaled treatment regimens via metered-dose inhaler bid (morning and evening) for 12 weeks: (1) FP 220 g (two puffs, 110 g/puff), placebo SL (two puffs), and placebo TAA (six puffs); (2) FP 88 g (two puffs, 44 g/puff), SL 42 g (two puffs, 21 g/puff), and placebo TAA (six puffs); or (3) TAA 600 g (six puffs, 100 g/puff), placebo FP (two puffs), and placebo SL (two puffs). FP was delivered as an aerosol suspension via a metereddose inhaler (Flovent Inhalation Aerosol; Glaxo Wellcome). Salmeterol was delivered as an aerosol suspension (Serevent Inhalation Aerosol; Glaxo Wellcome). Triamcinolone acetonide was delivered as an aerosol suspension via a metered-dose inhaler (Azmacort Oral Inhaler; Rhone-Poulenc Rorer Pharmaceuticals; Collegeville, PA) with an attached spacer device (Rhone-Poulenc Rorer Pharmaceuticals). The placebo oral inhalers were assembled using identical components to maintain double-blind, tripledummy study conditions. Albuterol aerosol as needed and theophylline (if part of an established fixed treatment regimen) were permitted during the study; however, albuterol had to be withheld for Ն 6 h and theophylline for 12 to 36 h prior to scheduled clinic visits.
Patients returned to the clinic at weeks 1, 2, 4, 6, 8, and 12. At each clinic visit, diary card information was assessed and pulmonary function tests were performed. The primary efficacy measure was morning predose FEV 1 . Other efficacy measures included patient-measured morning and evening PEF, albuterol aerosol use (and percent of rescue-free days), number of nighttime awakenings requiring inhaled albuterol, asthma symptom scores (and percent of symptom-free days), and physician global assessments.
Safety was assessed by adverse events and physical examinations (including evaluations for oropharyngeal candidiasis). Investigators indicated whether or not an adverse event was potentially drug-related (possibly, probably, or almost certainly related to study drug).
Statistical Analyses
All statistical tests were two-sided with a significance level of 0.05. This study was designed to provide at least 80% power to detect a difference in morning FEV 1 of 0.25 L, assuming a SD of 0.55 L. Analyses were based on data from the intent-to-treat population, consisting of all patients exposed to the study drug. Statistical testing was performed at end point, defined as the final evaluable measurement for the patient regardless of whether the patient completed the study. By-visit analyses were performed on all available data at that time point.
For change from baseline in FEV 1 , an analysis of covariance to test for treatment differences was conducted in which the model included treatment and investigator as main effect and baseline as covariate. For change from baseline in patient weekly means of PEF, symptom scores, albuterol use, nighttime awakenings, and percent symptom-free and rescue-free days, univariate analyses of covariance to test for treatment differences were conducted in which models included treatment as main effect and baseline as covariate. Pairwise comparisons between treatments were based on contrasts constructed from the appropriate analysis of covariance models.
Results
Six hundred eighty patients met the inclusion criteria and were randomly assigned to treatment. Randomization resulted in comparable treatment groups at baseline with respect to patient demographics, pulmonary function, and number of patients receiving beclomethasone dipropionate, TAA, or flunisolide during screening. The demographics and disposition of patients are shown in Table 1 . Table 2 presents the mean change from baseline to end point for various efficacy measures. Improvements in FEV 1 and FEV 1 percent predicted were significantly greater with FP, 220 g bid (0.34 L), and with FP, 88 g, plus SL 42, g bid (0.46 L), than with TAA, 600 g bid (0.25 L), by the first week (p Յ 0.027). These statistically significant improvements persisted throughout the study and at end point. At end point, patients in the FP, 88 g, plus SL, 42 g bid, group experienced significantly greater improvements in FEV 1 compared with patients in the FP, 220 g bid, group (p ϭ 0.018). Mean increases from baseline to end point FEV 1 were 0.58 L (27% improvement) with FP, 88 g, plus SL, 42 g bid (0.48 L; 23% improvement) with FP, 220 g bid (0.34 L; 16% improvement) with TAA, 600 g bid. Mean changes from baseline in FEV 1 at each visit and at end point are shown in Figure 1 . Figure 2 shows the mean change from baseline in morning PEF over the 12-week treatment period. Improvements in morning PEF (p Յ 0.009) and PEF percent predicted (p Յ 0.011) were significantly greater with FP, 220 g bid, than with TAA, 600 g bid, by week 2 and throughout the study. By week 3, the mean change in morning PEF was 32 L/min with FP, 220 g bid, and 12 L/min with TAA, 600 g bid. Statistically significant (p Ͻ 0.001) differences in mean change from baseline to end-point morning PEF between the FP, 88 g, plus SL, 42 g bid, and TAA, 600 g bid, treatment groups were observed by week 1 and were maintained throughout the duration of the study. Improvements in morning PEF were significantly (p Յ 0.036) greater with FP, 88 g, plus SL, 42 g bid, than with FP, 220 g bid, alone throughout the study except at week 12. At end point, the mean increases in morning PEF over baseline values in patients who switched to FP, 220 g bid, and FP, 88 g, plus SL, 42 g bid, were 47 L/min and 58 L/min, respectively, compared with 18 L/min with TAA 600 g bid. Similarly, improvements in evening PEF at end point and throughout the study were significantly greater with FP, 88 g, plus SL, 42 g bid (by week 1; p Ͻ 0.001), and FP, 220 g bid (by week 2; p Յ 0.042), compared with TAA, 600 g bid (data not shown).
Pulmonary Function
Albuterol Use, Nighttime Awakenings, Asthma Symptoms
At end point, FP, 220 g bid, significantly reduced albuterol use, nighttime awakenings, and overall symptom score, and increased the percentage of symptom-free days compared with TAA, 600 g bid. Patients treated with FP, 88 g, plus SL, 42 g bid, significantly (p Յ 0.001 vs FP and TAA) reduced albuterol use at end point by 63% (2.9 puffs/d), compared with reductions by FP, 220 g bid (49%; 2.4 puffs/d), and TAA, 600 g (Table 2) . Daily asthma symptom scores were significantly decreased from baseline to end point in the FP, 88 g, plus SL, 42 g bid, treatment group (p ϭ 0.004 vs TAA) compared with TAA, 600 g bid. Similarly, the percentage of symptom-free days also significantly increased from baseline to end point after treatment with FP, 88 g, plus SL, 42 g bid (p Ͻ 0.001), compared with TAA, 600 g bid.
Physician Global Assessment
Physicians rated the treatment as "effective" or "very effective" in 84%, 70%, and 59% of patients treated with FP, 88 g, plus SL, 42 g bid; FP, 220 g bid; and TAA, 600 g bid, treatment regimens, respectively (Fig 3) . These differences were statistically significant: FP plus SL vs TAA (p Ͻ 0.001); FP plus SL vs FP (p ϭ 0.001); and FP vs TAA (p ϭ 0.016).
Safety
All three treatments were well tolerated throughout the 12 weeks of the study. No clinically significant abnormalities were noted in physical examinations. No serious drug-related adverse events occurred. Thirty-three patients (14%) in the FP, 88 g, plus SL, 42 g bid, group; 30 patients (13%) in the FP, 220 g bid, group; and 19 patients (8%) in the TAA, 600 g bid, group experienced at least one adverse event during the study considered to be potentially related to treatment (p ϭ 0.104, overall). The most commonly reported (Ն 2% in any group) adverse events considered by the investigator to be potentially related to treatment are listed in Table 3 . Most adverse events were pharmacologically predictable events (eg, hoarseness, throat irritation, oropharyngeal candidiasis) that were commonly observed with the use of inhaled corticosteroids.
Of the 16 patients withdrawn due to adverse events, only 6 of these patients (3, 1, and 2 patients in the FP, 88 g, plus SL, 42 g bid; FP, 220 g bid; and TAA, 600 g bid, treatment groups, respectively) experienced adverse events considered by the investigator to be potentially related to study drug. Of the three patients in the FP, 88 g, plus SL, 42 g bid, group who withdrew from the study, one patient experienced hoarseness, the second chest cramps, and the third patient experienced facial swelling, headache, nasal congestion, nausea, and sore throat. The patient who withdrew in the FP, 220 g bid, group experienced dysphonia. One patient in the TAA, 600 g bid, group withdrew from the study because of irregular menses and thrush. The second patient in the TAA, 600 g bid, group withdrew as a result of tachycardia.
Discussion
The results of this study indicate that when asthma is not controlled by low doses of inhaled corticosteroids (as defined by NIH guidelines), improvements in FEV 1 and asthma symptom control are greater when patients switch (from beclomethasone dipropionate, TAA, or flunisolide) to medium-dose FP, 440 g/d, or combination therapy with low-dose FP, 176 g/d, plus SL, 84 g/d, than when they switch to medium-dose TAA, 1,200 g/d. In our study, switching to medium-dose FP, 440 g/d, significantly improved FEV 1 and all other efficacy measures (except percent rescue-free days), compared with increasing the dose of (or switching to) medium-dose TAA, 1,200 g/d. These data corroborate the findings of other studies that have shown significantly greater increases in FEV 1 and PEF as well as greater reductions in rescue albuterol use after 24 weeks of treatment with medium-dose FP, 500 g/d (administered twice daily), compared with low-dose TAA, 800 g/d (administered four times daily). 11, 12 However, in this study, medium doses of both FP and TAA (presumably therapeutically equivalent) were not therapeutically equivalent. These results reinforce the concept that inhaled corticosteroids are not equivalent on a per-puff or per-microgram basis, which may have implications for dosing recommendations of inhaled corticosteroids in clinical practice.
Both FP and TAA treatment regimens caused improvement in FEV 1 in the first week, but these improvements were significantly higher with FP, These data suggest that inhaled corticosteroids promote improvement in airway obstruction in the first 3 weeks that accounts for 67 to 88% of the total improvement in morning PEF and FEV 1 . Furthermore, the magnitude of the improvements was significantly greater for FP than for TAA. Szefler et al 16 retrospectively analyzed data from eight studies (n ϭ 1,461) and reported that the onset of significant benefit of FP on PEF, symptoms, and rescue albuterol use occurred within 1 day of therapy; FEV 1 improved within 1 week of the start of therapy. This trend suggests that comparison of corticosteroid effects in the first 3 weeks may help define the relative efficacies of these drugs.
Combination treatment was significantly more effective than switching to a moderate dose of FP 440 g/d in improving FEV 1 , reducing rescue albuterol use, and increasing the percent of rescue-free days. Although no significant end-point differences were noted between combination treatment and FP 440 g/d in PEF, overall symptom scores, or nighttime awakenings, the trends in improvement generally favored the combination regimen. This lack of significant difference is likely a result of low symptom scores and number of nighttime awakenings at baseline, which left little room for improvement in these measures. These data are consistent with the results of other studies that demonstrated greater improvements in FEV 1 after combination treatment with an inhaled corticosteroid and a long-acting ␤ 2 -agonist bronchodilator. 17, 18 The mechanisms by which these improvements occur with the addition of a longacting bronchodilator remain unknown. However, it has recently been shown that ␤ 2 -agonists are potent activators of the glucocorticoid receptor. 19 In addition, it is likely that regular use of inhaled corticosteroids modulates ␤ 2 -agonist receptor function. 20 Adverse event profiles were similar among treatment groups in this study. Although more extensive safety evaluations were not conducted in our study, the comparable safety profiles of FP (powder, 200 to 1,000 g/d; metered-dose inhaler, 176 to 440 g/d), TAA (600 to 1,000 g/d), and placebo have previously been established by other investigators. 21, 22 Furthermore, in previous efficacy and safety comparisons of FP, 500 g/d, and TAA, 800 g/d, FP demonstrated increased efficacy with no difference in effect on the hypothalamic-pituitary-adrenocortical axis (as measured by morning plasma cortisol concentrations). 11, 12 In summary, results from this study support the most current NIH guidelines for the treatment of asthma that recommend either increasing the dose of inhaled corticosteroid (to medium-dose) or adding a long-acting ␤ 2 -agonist bronchodilator in patients with persistent asthma who are symptomatic while taking low doses of inhaled corticosteroids. 1 However, this is the first study to demonstrate the value of switching these patients to FP alone (mediumdose), or to FP (low-dose) in combination with a long-acting inhaled ␤ 2 -agonist. Although improvement in pulmonary function and asthma symptom control was noted after an increased dosage of TAA (1,200 g/d), greater benefits were observed in the group that switched to a lower microgram dosage of FP (440 g/d). The largest improvements were evident with the lowest recommended dose of FP (176 g/d) combined with SL. Finally, in future studies evaluating the efficacy and safety of inhaled corticosteroids, therapeutically appropriate doses should be used to provide more clinically relevant comparative information. 
